Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
From Flower to Pharmacy: The Science Behind Manuka Honey
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Breakthroughs in the Lab – Blind Spots in Reality
Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....
Raising Expectations for Medical Liaisons
In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...
Thousands Benefit From New Treatment for Advanced Prostate Cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23...
Novo Nordisk and Aspect Biosystems Expand Diabetes Collaboration
Novo Nordisk and Aspect Biosystems expand collaboration to accelerate curative diabetes therapies The landscape of regenerative medicine has shifted significantly following the announcement that Novo Nordisk and Aspect Biosystems are entering a comprehensive new phase...
GSK Makes $2.2 Billion Bid for RAPT Therapeutics
GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...
Communication Breakdown: Why Soft Skills Are More Important Than Ever in Life Sciences
We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter. Some of those difficult people will be highly competent in their...
Metformin and Type 2 Diabetes: Benefits, Limitations and the Role of Diet
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Part III – China’s Biopharma Scale: Deals, Reimbursement and GLP-1s
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
J&J Axes Eczema Drug From $1.25B Acquisition
Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...
How the UK May Be Undervaluing Life Sciences Manufacturing Investments
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
Part II – Trade, Capital and the UK Life Sciences Strategy
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Manufacturing and Supply Chain Resilience for Advanced Therapies
Manufacturing and supply chain resilience has moved to the forefront of strategic planning across the life sciences industry as advanced therapies place unprecedented strain on existing production models. Cell therapies, gene therapies, mRNA platforms and increasingly...
Part I – Platforms, Pipelines and Incentives in Global Biopharma
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...







